Abstract：
This guidance refers to urogenital atrophy, a chronic and progressive condition due to estrogen deficiency, most commonly associated with the menopause. There is a potential negative impact on all urogenital tissue quality including the vulva, vagina, bladder and urethra. Symptoms may not become apparent for several years after the menopause and therefore any association is lost, with women accepting symptoms as a normal part of the aging process. There may be reluctance to discuss symptoms with a clinician and this is likely to be linked with under diagnosis and under treatment. Urogenital atrophy has been described as a silent epidemic with lack of awareness affecting an accurate diagnosis and access to treatment. Whilst vaginal estrogen (also referred to as local estrogen) therapy is the best-known treatment, newer drugs and interventions are now available.
摘要：
这个指南指的是泌尿生殖器萎缩，由于雌激素缺乏导致的慢性和进行性疾病，最常与更年期有关。对包括外阴在内的所有泌尿生殖道组织质量都有潜在的负面影响，阴道,膀胱和尿道.绝经后几年症状可能不会变得明显，因此任何关联都会消失，女性接受症状作为衰老过程的正常部分。可能不愿与临床医生讨论症状，这可能与诊断和治疗有关。泌尿生殖器萎缩已被描述为一种无声的流行病，缺乏意识会影响准确的诊断和获得治疗。虽然阴道雌激素（也称为局部雌激素）疗法是最著名的治疗方法，现在有了新的药物和干预措施。
